OncoSec forms SAB
This article was originally published in Scrip
OncoSec Medical, a developer of novel OMS ElectroOncology therapies, has recruited a scientific advisory board consisting of: Dr Richard Heller, director of the Frank Reidy Research Center for Bioelectrics at Old Dominion University; Dr Iacob Mathieson, CEO of Otivio and co-founder of Inovio, where he is now a member of the SAB; and Dr Christian Ottensmeier, professor of experimental cancer research at the University of Southampton. The board will meet bi-annually to review the company's progress in research and clinical development, and will rely on input and expertise from OncoSec's clinical and scientific advisory panel.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.